SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-23-025650
Filing Date
2023-02-06
Accepted
2023-02-06 16:32:54
Documents
1
Group Members
NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P. (BIOPHARMA II)NEW LEAF BPO ASSOCIATES II, L.P.NEW LEAF BPO MANAGEMENT II, L.L.C.NEW LEAF VENTURE ASSOCIATES III, L.P.NEW LEAF VENTURE MANAGEMENT III, L.L.C.RONALD M. HUNTVIJAY K. LATHI

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d412071dsc13ga.htm SC 13G/A 147405
  Complete submission text file 0001193125-23-025650.txt   149384
Mailing Address C/O NEW LEAF VENTURE PARTNERS 7 TIMES SQUARE, SUITE 3502 NEW YORK NY 10036
Business Address C/O NEW LEAF VENTURE PARTNERS 7 TIMES SQUARE, SUITE 3502 NEW YORK NY 10036 646-871-6400
New Leaf Ventures III, L.P. (Filed by) CIK: 0001625653 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-443-7400
Harpoon Therapeutics, Inc. (Subject) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90935 | Film No.: 23591135
SIC: 2836 Biological Products, (No Diagnostic Substances)